Prestige BioPharma Limited (950210.KS)

KRW 15200.0

(0.33%)

Gross Profit Summary of Prestige BioPharma Limited

  • Prestige BioPharma Limited's latest annual gross profit in 2023 was 689.07 Million KRW , down -465.17% from previous year.
  • Prestige BioPharma Limited's latest quarterly gross profit in 2023 Q4 was -137.09 Million KRW , up 96.43% from previous quarter.
  • Prestige BioPharma Limited reported a annual gross profit of -11.49 Billion KRW in annual gross profit 2022, down -197.14% from previous year.
  • Prestige BioPharma Limited reported a annual gross profit of -3.86 Billion KRW in annual gross profit 2021, down -132.08% from previous year.
  • Prestige BioPharma Limited reported a quarterly gross profit of -3.83 Billion KRW for 2023 Q3, down -3.06% from previous quarter.
  • Prestige BioPharma Limited reported a quarterly gross profit of -137.09 Million KRW for 2023 Q4, up 96.43% from previous quarter.

Annual Gross Profit Chart of Prestige BioPharma Limited (2023 - 2017)

Historical Annual Gross Profit of Prestige BioPharma Limited (2023 - 2017)

Year Gross Profit Gross Profit Growth
2023 689.07 Million KRW -465.17%
2022 -11.49 Billion KRW -197.14%
2021 -3.86 Billion KRW -132.08%
2020 -1.66 Billion KRW -40.64%
2019 -1.18 Billion KRW -188.88%
2018 1.33 Billion KRW 655.15%
2017 -240.23 Million KRW 0.0%

Peer Gross Profit Comparison of Prestige BioPharma Limited

Name Gross Profit Gross Profit Difference
ORIENT BIO Inc. 9.58 Billion KRW 92.81%
Green Cross Holdings Corporation 603.58 Billion KRW 99.886%
Green Cross Holdings Corporation 458.68 Billion KRW 99.85%
Pharmicell Co., Ltd. 14.95 Billion KRW 95.392%
Green Cross Corporation 458.68 Billion KRW 99.85%
GeneOne Life Science, Inc. -14.98 Billion KRW 104.599%
Celltrion, Inc. 1010.9 Billion KRW 99.932%
Samsung Biologics Co.,Ltd. 1802.76 Billion KRW 99.962%
SK bioscience Co.,Ltd. 142.24 Billion KRW 99.516%
SK Biopharmaceuticals Co., Ltd. 308.37 Billion KRW 99.777%